Universität zu Köln

Al-Sawaf, Othman and Fischer, Kirsten (2021). TP53 mutations in CLL: does frequency matter? Blood, 138 (25). S. 2600 - 2602. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Full text not available from this repository.

Abstract

In this issue of Blood, Malcikova et al demonstrate that low-burden TP53 mutations with variant allele frequencies (VAFs) between 0.1% and 10% have a significant adverse impact on overall survival (OS), although they do not affect event-free survival (EFS) after first-line chemoimmunotherapy.(1) The authors observed clonal expansion of TP53 mutations, particularly in patients treated with fludarabine, cyclophosphamide, and rituximab, whereas patients managed with watch-and-wait approaches or targeted agents did not show significant clonal expansion.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Al-Sawaf, Othman UNSPECIFIED UNSPECIFIED UNSPECIFIED Fischer, Kirsten UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-572739
DOI:	10.1182/blood.2021012343
Journal or Publication Title:	Blood
Volume:	138
Number:	25
Page Range:	S. 2600 - 2602
Date:	2021
Publisher:	AMER SOC HEMATOLOGY
Place of Publication:	WASHINGTON
ISSN:	1528-0020
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CLINICAL IMPACT Multiple languages Hematology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/57273